- Home
- BLNK vs CRDF Comparison
BLNK vs CRDF Comparison
Compare BLNK & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNK
- CRDF
- Stock Information
- Founded
- BLNK 2009
- CRDF 1999
- Country
- BLNK United States
- CRDF United States
- Employees
- BLNK N/A
- CRDF N/A
- Industry
- BLNK Industrial Specialties
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLNK Consumer Discretionary
- CRDF Health Care
- Exchange
- BLNK Nasdaq
- CRDF Nasdaq
- Market Cap
- BLNK 129.3M
- CRDF 144.4M
- IPO Year
- BLNK N/A
- CRDF N/A
- Fundamental
- Price
- BLNK $2.30
- CRDF $2.38
- Analyst Decision
- BLNK Buy
- CRDF Strong Buy
- Analyst Count
- BLNK 8
- CRDF 5
- Target Price
- BLNK $2.54
- CRDF $11.10
- AVG Volume (30 Days)
- BLNK 6.8M
- CRDF 799.1K
- Earning Date
- BLNK 11-06-2025
- CRDF 11-06-2025
- Dividend Yield
- BLNK N/A
- CRDF N/A
- EPS Growth
- BLNK N/A
- CRDF N/A
- EPS
- BLNK N/A
- CRDF N/A
- Revenue
- BLNK $104,788,000.00
- CRDF $545,000.00
- Revenue This Year
- BLNK N/A
- CRDF N/A
- Revenue Next Year
- BLNK $19.30
- CRDF N/A
- P/E Ratio
- BLNK N/A
- CRDF N/A
- Revenue Growth
- BLNK N/A
- CRDF N/A
- 52 Week Low
- BLNK $0.63
- CRDF $1.90
- 52 Week High
- BLNK $2.65
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- BLNK 80.69
- CRDF 52.67
- Support Level
- BLNK $1.47
- CRDF $1.99
- Resistance Level
- BLNK $2.65
- CRDF $2.27
- Average True Range (ATR)
- BLNK 0.20
- CRDF 0.09
- MACD
- BLNK 0.09
- CRDF 0.05
- Stochastic Oscillator
- BLNK 96.78
- CRDF 93.34
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.